In a blow to Catalyst Pharmaceuticals (CPRX), a federal judge dismissed its lawsuit accusing the Food and Drug Administration of violating the law when it approved a similar medicine by a small, family-run rival company.

The lawsuit has been closely watched because Catalyst raised thorny questions about regulatory standards and the vagaries of orphan drug designations, while also playing into the heated national debate over the rising cost of prescription medicines. But in an 18-page order, U.S. District Court Judge Beth Bloom maintained Catalyst staked out differing interpretations of federal law and FDA regulations that did not support its case.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Call this ‘damning with faint praise’? “The Jacobus drug costs less than half of the Catalyst drug, by the way.” Less than half of $375,000 seems to indicate $150K+ … no, I’m not doing the research for an exact number, but that’s “way more than $750.”

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy